

**In the Claims:**

1 . (currently amended) At least one isolated mammalian anti-TNF antibody, comprising at least one variable region comprising SEQ ID NO:7 and [or] 8.

2 . (original)An TNF antibody according to claim 1, wherein said antibody binds TNF with an affinity of at least one selected from at least  $10^{-9}$  M, at least  $10^{-10}$  M, at least  $10^{-11}$  M, or at least  $10^{-12}$  M.

3 . (original)An TNF antibody according to claim 1, wherein said antibody substantially neutralizes at least one activity of at least one TNF protein.

Claims 4-8 (canceled).

9. (currently amended) A composition comprising at least one isolated mammalian anti-TNF antibody having at least one variable region comprising SEQ ID NO:7 and [or] 8, and at least one pharmaceutically acceptable carrier or diluent.

Claims 10-15 (canceled).

16. (currently amended) A medical device, comprising at least one isolated mammalian anti-TNF antibody having at least one variable region comprising SEQ ID NO:7 and [or] 8, wherein said device is suitable to contacting or administering said at least one anti-TNF antibody by at least one mode selected from parenteral, subcutaneous, intramuscular, intravenous, intrarticular, intrabronchial, intraabdominal, intracapsular, intracartilaginous, intracavitary, intracelial, intracelebellar, intracerebroventricular, intracolic, intracervical, intragastric, intrahepatic, intramyocardial, intraosteal, intrapelvic, intrapericardiac, intraperitoneal, intrapleural, intraprostatic, intrapulmonary, intrarectal, intrarenal, intraretinal, intraspinal, intrasynovial, intrathoracic, intrauterine, intravesical, bolus, vaginal, rectal, buccal, sublingual, intranasal, or transdermal.

Claims 17-101 (canceled).